Krishnan Nandabalan Bio Xcel Therapeutics, Inc. (BTAI) insider trading activity

Krishnan Nandabalan is Director of BioXcel Therapeutics, Inc.. Currently has a direct ownership of 0 shares of BTAI, which is worth approximately $0. The most recent transaction as insider was on Apr 06, 2023, when has been sold 60,000 shares (Common Stock) at a price of $17.32 per share, resulting in proceeds of $1,039,200. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Krishnan Nandabalan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held	Form
Date	Transaction	Value	Shares Traded	Shares Held	Form
Apr 06 2023	SELL Open market or private sale	$1,039,200 $17.32 p/Share	60,000 Reduced 100.0%	0 Common Stock
Apr 06 2023	BUY Exercise of conversion of derivative security	$24,600 $0.41 p/Share	60,000 Added 50.0%	60,000 Common Stock
Jan 05 2023	SELL Open market or private sale	$585,868 $22.63 p/Share	25,889 Reduced 100.0%	0 Common Stock
Jan 05 2023	BUY Exercise of conversion of derivative security	$10,614 $0.41 p/Share	25,889 Added 50.0%	25,889 Common Stock
Jan 04 2023	SELL Open market or private sale	$747,030 $21.9 p/Share	34,111 Reduced 100.0%	0 Common Stock
Jan 04 2023	BUY Exercise of conversion of derivative security	$13,985 $0.41 p/Share	34,111 Added 50.0%	34,111 Common Stock
Nov 11 2022	SELL Open market or private sale	$488,250 $15.0 p/Share	32,550 Reduced 100.0%	0 Common Stock
Nov 11 2022	BUY Exercise of conversion of derivative security	$13,345 $0.41 p/Share	32,550 Added 50.0%	32,550 Common Stock
Nov 10 2022	SELL Open market or private sale	$411,750 $15.0 p/Share	27,450 Reduced 100.0%	0 Common Stock
Nov 10 2022	BUY Exercise of conversion of derivative security	$11,254 $0.41 p/Share	27,450 Added 50.0%	27,450 Common Stock
Jul 24 2020	BUY Other acquisition or disposition	$4,860,800 $60.76 p/Share	80,000 Added 50.0%	80,000 Common Stock
Apr 01 2019	SELL Bona fide gift	-	1,000 Reduced 100.0%	0 Common Stock

Krishnan Nandabalan

Director

New Haven, CT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BTAI shares.

Notify only if

Value

Any

Insider Trading

Get notified when an Bio Xcel Therapeutics, Inc. insider buys or sells BTAI shares.

Notify only if

Operation

Any

Value

Any

Type

P - Open market or private purchase×

S - Open market or private sale×

V - Transaction voluntarily reported earlier than required×

A - Grant, award, or other acquisition×

D - Sale (or disposition) back to the issuer×

F - Payment of exercise price or tax liability×

I - Discretionary transaction×

M - Exercise of conversion of derivative security×

C - Conversion of derivative security×

E - Expiration of short derivative position×

H - Expiration (or cancellation) of long derivative position with value received×

O - Exercise of out-of-the-money derivative securities×

X - Exercise of in-the-money or at-the-money derivatives securities×

G - Bona fide gift×

L - Small Acquisition×

W - Acquisition or disposition by will or laws×

Z - Deposit into or withdrawal from voting trust×

J - Other acquisition or disposition×

K - Transaction in equity swap or similar instrument×

U - Disposition due to a tender of shares in a change of control transaction×

20 item(s) selected

News

Receive news related to BioXcel Therapeutics, Inc.

Track Activities on BTAI

Account